arrow
C

Christopher P. Denton

university college london
H指数:110
被引数:5.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Demographic and clinical features of systemic sclerosis patients with anti-U1RNP antibodies: an European Scleroderma Trials and Research (EUSTAR) analysis

抗U1RNP抗体系统性硬化症患者的流行病学和临床特征:欧洲硬皮病试验和研究(EUSTAR)分析

2026-09-220
OAAI
Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study

系统性硬化症相关肺动脉高压患者口服抗凝剂的有效性:一项EUSTAR队列研究

2026-09-180
OAAI
Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort

系统性硬化症中JAK抑制剂的实时安全性和有效性:来自EUSTAR队列的倾向性匹配研究

2026-09-080
OAAI
Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management

合并症和患者人口统计学特征对雷诺现象症状特征的影响:对诊断和管理的启示

2026-05-260
PRE
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice

系统性硬化病相关性间质性肺疾病:我们了解的情况以及如何将指南融入临床实践

CHEST
IF8.6
2025-12-130
PRE
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial

一种预测系统性硬化症改良Rodnan皮肤评分的复合生物标志物评分:来自自体干细胞移植国际硬皮病试验的见解

2025-12-100
OAAI
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis

利用统一的血管框架来预测器官特异性并发症并实现系统性硬化病的疾病修饰

2025-10-140
PRE
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis

“我这样做对吗?”——医师对系统性硬化症临床试验中全球评估的看法

2025-09-010
OAAI